Listed by the USPTO as LEE, WILLIAM Y
Tech Center 1600 • Art Units: 1623 1626 1629
This examiner grants 48% of resolved cases
LEE, WILLIAM Y is assigned to Tech Center 1600 and Art Unit 1623. The profile includes 711 resolved cases and records a 48.0% allowance rate. The median time to allowance is 1170 days, indicating that applicants should plan for both a challenging outcome pattern and an extended prosecution timeline.
The interview lift is 34.1%, making interviews an important consideration in prosecution strategy. Sydnexis, Sage Therapeutics, and Spruce Biosciences are the leading listed companies. WILSON SONSINI GOODRICH & ROSATI, BakerHostetler, and Knobbe Martens are the leading listed firms. The company mix is concentrated in therapeutic and life sciences work.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17727519 | Method of Treating Colorectal Cancers Using a PKC Inhibitor | Final Rejection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 18291083 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Non-Final OA | NOVARTIS AG |
| 18567952 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18383256 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | Non-Final OA | The Regents Of the University of California |
| 18201882 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Non-Final OA | Flagship Pioneering Innovations V, Inc. |
| 18237705 | COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18684808 | QUINACRINE AND DERIVATIVES THEREOF FOR TREATMENT OF VIRAL INFECTIONS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18113981 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18784718 | OPHTHALMIC COMPOSITION | Final Rejection | Sydnexis, Inc. |
| 17894882 | OPHTHALMIC COMPOSITION | Final Rejection | Sydnexis, Inc. |
| 17894884 | OPHTHALMIC COMPOSITION | Final Rejection | Sydnexis, Inc. |
| 17894885 | OPHTHALMIC COMPOSITION | Final Rejection | Sydnexis, Inc. |
| 18280357 | Pelargonic Acid for Use Against Viral Infections | Non-Final OA | Nutrition Sciences N.V. |
| 17874522 | GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS | Final Rejection | Individual inventor |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy48.0% of resolved applications examined by William Y Lee were allowed (711 resolved cases), compared with 51.3% across Art Unit 1623 over the last five years.
This examiner's interview lift is +34.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by William Y Lee took 1,170 days on average from filing to allowance.
William Y Lee examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
